<?xml-stylesheet type='text/xsl' href='ctgovTransform.xsl'?>
<CT.GOV_Trial requestNumber="6717">
  <stage>Registered</stage>
  <submitdate>18/09/2017</submitdate>
  <approvaldate>18/09/2017</approvaldate>
  <nctid>NCT03290560</nctid>
  <trial_identification>
    <studytitle>Evaluation to Assess Safety and Tolerability of DM199 in Subjects With Acute Ischemic Stroke</studytitle>
    <scientifictitle>A Randomized, Double-blind, Placebo-controlled Phase II Multi-Center Evaluation to Assess the Safety and Tolerability of DM199 Administered Intravenously and Subcutaneously in Subjects With Acute Ischemic Stroke</scientifictitle>
    <utrn />
    <trialacronym>REMEDY</trialacronym>
    <secondaryid>DM199-2017-001</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Acute Ischemic Stroke</healthcondition>
    <conditioncode>
      <conditioncode1>Stroke</conditioncode1>
      <conditioncode2>Haemorrhagic</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Stroke</conditioncode1>
      <conditioncode2>Ischaemic</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Cardiovascular </conditioncode1>
      <conditioncode2>Diseases of the vasculature and circulation including the lymphatic system</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Neurological</conditioncode1>
      <conditioncode2>Other neurological disorders</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Treatment: drugs - Recombinant human tissue kallikrein
Other interventions - Placebo

Experimental: Recombinant human tissue kallikrein - A single IV infusion of 1 microgram/kg followed by 8 subcutaneous injections of 3 microgram/kg occurring every 72 hours.

Placebo Comparator: Placebo - A single IV infusion of 1 microgram/kg followed by 8 subcutaneous injections of 3 microgram/kg occurring every 72 hours.


Treatment: drugs: Recombinant human tissue kallikrein
Recombinant human tissue kallikrein

Other interventions: Placebo
Placebo Comparator: Phosphate buffered saline

</interventions>
    <comparator />
    <control />
    <interventioncode>Treatment: drugs</interventioncode>
    <interventioncode>Other interventions interventions</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Number of participants with treatment-related adverse events as assessed by CTCAE v4.3 - Assessed by total number and severity of all treatment-related adverse events.</outcome>
      <timepoint>90 Days</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Changes from baseline to Day 90 of NIH Stroke Scale. - Assessed by a reduction in points from baseline.</outcome>
      <timepoint>90 Days</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Changes from baseline to Day 90 of Barthel Index. - Assessed by an increase in points from baseline.</outcome>
      <timepoint>90 Days</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Changes from baseline to Day 90 of Modified Rankin Scale. - Assessed by a reduction in points from baseline.</outcome>
      <timepoint>90 Days</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>1. Subject is &gt;/= 18 years of age

          2. Subject has been diagnosed with acute ischemic stroke with onset = 24 hours from
             enrollment.

          3. Subject has NIH stroke score (NIHSS) = 6 and = 25.

          4. Subject or legally authorized representative is willing and able to sign written
             informed consent.</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage />
    <inclusivemaxagetype>No limit</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>1. Subject has improvement in the NIH stroke scale as reflected by a reduction in = 4
             points from baseline at any time prior to enrollment.

          2. Subject is currently prescribed angiotensin-converting-enzyme inhibitors (ACEi) and is
             unable or unwilling to convert to another antihypertensive pharmacological treatment
             for the duration of the study.

          3. Subject has a history of significant allergic diathesis such as urticaria, angioedema
             or anaphylaxis.

          4. Subjects with current malignancy or active malignancy = 5 years prior to enrollment
             except basal cell or squamous cell carcinoma of the skin or in situ cervical cancer
             that has undergone potentially curative therapy and at least six months have elapsed
             since the procedure.

          5. Subject has a history of clinically significant acute bacterial, viral, or fungal
             systemic infections in the last four weeks prior to enrollment.

          6. Subject has clinical or laboratory evidence of an active infection at the time of
             enrollment.

          7. Subject has known alpha 1-antitrypsin deficiency (a1-antitrypsin deficiency).

          8. Subject has a known diagnosis of human immunodeficiency virus (HIV), hepatitis B
             surface antigen (HBsAg), or anti-hepatitis C virus (Anti-HCV) at screening.

          9. Subject is pregnant or nursing.

         10. Subject is male or female of childbearing potential, is participating in heterosexual
             sexual activity that could lead to pregnancy, and is unable or unwilling to practice
             medically effective contraception during the study.

         11. Subject is participating in any other drug study = 4 weeks or 5 half-lives of the
             investigational product, whichever is longer.

         12. Subject does not have sufficient venous access for infusion of study treatment or
             blood sampling.

         13. In the opinion of the Investigator, subject is unlikely to be followed for the
             duration of t the study.

         14. Subject is unable or unwilling to comply with protocol requirements, including
             assessments, tests, and follow-up visits.

         15. Subject has any other medical condition which in the opinion of the Investigator will
             make participation medically unsafe or interfere with the study results.</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment />
    <sequence />
    <masking>Blinded (masking used)</masking>
    <assignment>Parallel</assignment>
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1>The people receiving the treatment/s</masking1>
    <masking2 />
    <masking3 />
    <masking4>The people analysing the results/data</masking4>
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 2</phase>
    <anticipatedstartdate>20/11/2017</anticipatedstartdate>
    <actualstartdate />
    <anticipatedenddate />
    <actualenddate />
    <samplesize>60</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Not yet recruiting</recruitmentstatus>
    <anticipatedlastvisitdate>20/06/2019</anticipatedlastvisitdate>
    <actuallastvisitdate />
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate>VIC</recruitmentstate>
    <hospital>Royal Melbourne Hospital - Parkville</hospital>
    <postcode>3050 - Parkville</postcode>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Commercial sector/Commercial sector/Industry</primarysponsortype>
    <primarysponsorname>DiaMedica USA Inc.</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry />
  </sponsorship>
  <ethicsAndSummary>
    <summary>This is a Phase II study to assess the safety and tolerability of DM199 in acute ischemic
      stroke patients. The study will be randomized, placebo controlled at multiple centers.</summary>
    <trialwebsite>https://clinicaltrials.gov/show/NCT03290560</trialwebsite>
    <publication />
    <ethicsreview />
    <publicnotes />
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Bruce Campbell</name>
      <address>Melbourne Health</address>
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title />
      <name>Kari Peterson</name>
      <address />
      <phone>763-496-5199</phone>
      <fax />
      <email>kpeterson@diamedica.com</email>
      <country />
      <type>Public Queries</type>
    </contact>
  </contacts>
</CT.GOV_Trial>